Durvalumab vs Moxifloxacin

Durvalumab vs Moxifloxacin: Overview

This comparison examines the pharmacological differences between Durvalumab and Moxifloxacin.

Mechanism of Action

Durvalumab: Human IgG1 kappa anti-PD-L1 monoclonal antibody blocking PD-L1 binding to PD-1 and CD80.

Moxifloxacin: Fourth-generation fluoroquinolone inhibiting DNA gyrase and topoisomerase IV with enhanced anaerobic activity.

Pharmacokinetics

Half-life: Durvalumab — 17 days; Moxifloxacin — 12 hours.

Chemical Properties

Molecular Formula: Moxifloxacin — C21H24FN3O4.

Molecular Weight: Moxifloxacin — 401.4350 g/mol.

Type: Durvalumab — Antibody; Moxifloxacin — Small molecule.